Total Funding
68
59
Total FundingPost-IPO Equity raised
Growth Score
-22 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
87709
Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.
- David Elsley: President & CEO
Trevor Burns: Investor RelationsPast Role: American CuMo Mining Corporation, CFO
About the Company
Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure.
Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two
important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.
